Market Overview

Clovis Upgraded At Credit Suisse Following Acquisition Rumor


Clovis Oncology Inc (NASDAQ: CLVS) is a potential takeout target for a global pharma company, Credit Suisse’s Kennen MacKay said in a report. He upgraded the rating on the company from Neutral to Outperform, while raising the price target from $19 to $41.

Following the FDA’s acceptance of Clovis’ rucaparib NDA in 3L g/sBRCA treatment, data at the forthcoming ESMO conference would offer greater insight into rucaparib’s competitive profile versus Lynparza and efficacy in platinum resistant/refractory patients, analyst MacKay mentioned.

Potential Acquisition

“We have conducted an acquisition scenario analysis for parties that have expressed interest in acquiring US oncology companies,” MacKay commented. He named the following companies among others as being potential buyers:

  • Eli Lilly and Co (NYSE: LLY)
  • Merck & Co., Inc.(NYSE: MRK)
  • Takeda Pharmaceutical Co Ltd (OTCMKTS: TKPYY)

The analyst added that Clovis could be worth $35-$41 per share on operational synergies, and $52-$55 per share with leveraged tax benefits.

“Our base-case M&A DCF assumes a -50% cut to CLVS R&D, -50% cut to CLVS SG&A, no change to CLVS COGS, a 35% tax rate, and a 10% increase in product sales. We view this as a conservative M&A valuation, given an acquirer could potentially see tax synergies and further increases to product sales,” MacKay wrote. He added that currently M&A potential outweighs concerns.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for CLVS

Feb 2019Initiates Coverage OnBuy
Oct 2018MaintainsOverweightOverweight
Oct 2018DowngradesOverweightNeutral

View More Analyst Ratings for CLVS
View the Latest Analyst Ratings

Posted-In: Credit Suisse Kennen MacKayAnalyst Color Long Ideas Upgrades Price Target Analyst Ratings Trading Ideas


Related Articles (LLY + CLVS)

View Comments and Join the Discussion!

Bank Of Japan Has Turned Into 'Control Freaks'

Can You Guess This Chart?